Gray Matter Alterations in Adults with Attention-Deficit/Hyperactivity Disorder Identified by Voxel Based Morphometry
Authors:
- Larry J. SeidmanLSLarry J. Seidman
- Joseph BiedermanJBJoseph Biederman
- Lichen LiangLLLichen Liang
- Eve M. ValeraEVEve M. Valera
- Michael C. MonuteauxMMMichael C. Monuteaux
- Ariel BrownABAriel Brown
- Jonathan KaiserJKJonathan Kaiser
- Thomas SpencerTSThomas Spencer
- Stephen V. FaraoneSFStephen V. Faraone
- Nikos MakrisNMNikos Makris
- 1 May 2011
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 69 (9) , 857-866
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health
- March of Dimes Foundation
- Mental Illness and Neuroscience Discovery Institute
- Commonwealth Research Center of the Massachusetts Department of Mental Health
- National Research Service Award (MH065040-01A1)
- Peter Livingston
- Clinical Research Training Program (MH 16259, MH 071535, MH 57934)
- National Alliance for Research on Schizophrenia and Depression Distinguished Investigator
- Johnson and Johnson Center for the Study of Psychopathology
- the National Center for Research Resources (P41RR14075)
- Janssen Pharmaceutica
- Alza
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Co.
- Janssen Pharmaceuticals Inc.
- McNeil
- Merck
- Organon
- Otsuka
- Shire
- NIMH
- National Institute of Child Health and Human Development
- Abbott
- AstraZeneca
- Celltech
- Cephalon
- Eli Lilly and Co.
- Eisai
- Forest
- Glaxo
- Gliatech
- Janssen
- McNeil
- National Alliance for Research on Schizophrenia and Depression
- National Institute on Drug Abuse
- New River
- Novartis
- Noven
- Neurosearch
- Pfizer
- Pharmacia
- The Prechter Foundation
- Shire
- The Stanley Foundation
- UCB Pharma Inc.
- Wyeth
- Shire Laboratories Inc.
- Eli Lilly and Company
- GlaxoSmith-Kline
- Janssen Pharmaceutical
- McNeil Pharmaceutical
- Novartis Pharmaceuticals
- Cephalon
- Pfizer
- National Institute of Mental Health
- Eli Lilly
- Pfizer
- Shire
- National Institutes of Health
- Eli Lilly
- Shire
- Pfizer
- National Institutes of Health
This publication has 80 references indexed in Scilit:
- Basal Ganglia Surface Morphology and the Effects of Stimulant Medications in Youth With Attention Deficit Hyperactivity DisorderAmerican Journal of Psychiatry, 2010
- Attention-Deficit/Hyperactivity Disorder and Attention NetworksNeuropsychopharmacology, 2009
- Can voxel based morphometry, manual segmentation and automated segmentation equally detect hippocampal volume differences in acute depression?NeuroImage, 2009
- Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inferenceNeuroImage, 2009
- Structural brain change in Attention Deficit Hyperactivity Disorder identified by meta-analysisBMC Psychiatry, 2008
- Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturationProceedings of the National Academy of Sciences, 2007
- Towards further understanding of the co-morbidity between attention deficit hyperactivity disorder and bipolar disorder: a MRI study of brain volumesPsychological Medicine, 2007
- Is attention deficit hyperactivity disorder a valid diagnosis in the presence of high IQ? Results from the MGH Longitudinal Family Studies of ADHDJournal of Child Psychology and Psychiatry, 2007
- Meta-Analysis of Intellectual and Neuropsychological Test Performance in Attention-Deficit/Hyperactivity Disorder.Neuropsychology, 2004
- Voxel-Based Morphometry—The MethodsNeuroImage, 2000